LLY.BA is trading 2.3% down at $33,220.00 as the stock pulls back following a period of strong momentum and no new company-specific news.
- The move is characterized as normal volatility and profit-taking after the stock gave back part of last week’s sharp gains and the prior session’s positive move.
- Recent momentum had been supported by a positive EU regulatory opinion for Jaypirca in chronic lymphocytic leukemia, but no fresh catalysts or analyst calls were identified on June 30, 2026.